Alcobra Ltd. (ADHD)

Trade ADHD now with
11/16/2017 7:09:56 AM Arcturus Completes Merger With Alcobra
11/9/2017 7:55:59 AM Alcobra Q3 Loss Per Share $0.09 Vs Loss $0.28 Prior Year
10/9/2017 9:39:11 AM WBB Securities Raises Alcobra Ltd. (ADHD) To Buy From Hold With $2 Price Target
6/12/2017 8:37:52 AM Alcobra Announces Cooperation Agreement With Brosh Group; To Continue Strategic Alternatives; Adds Two Directors
5/30/2017 8:10:20 AM Alcobra Q1 Loss Per Share $0.13 Vs Loss $0.18 Prior Year
5/15/2017 8:10:55 AM Alcobra CEO Yaron Daniely To Step Down, Effective May 31, David Baker Named Interim CEO
11/2/2016 9:30:43 AM WBB Securities Ups Alcobra Ltd. (ADHD) To Hold From Sell With $1.90 Price Target
10/7/2016 8:49:47 AM Alcobra Receives Written Full Clinical Hold Notice From The Division Of Psychiatry Products Of FDA
9/12/2016 9:23:18 AM WBB Securities Downgrades Alcobra Ltd. (ADHD) To Sell From Hold With $4 Price Target
8/30/2016 7:09:37 AM Alcobra Q2 Loss Per Share $0.21 Vs Loss $0.24 Last Year
7/19/2016 8:07:26 AM Alcobra Granted European Orphan Drug Designation For Metadoxine In Fragile X Syndrome
10/23/2014 3:14:46 PM FBR Capital Markets Downgrades Alcobra Ltd. (ADHD) To Market Perform From Outperform With $4.00 Price Target